3-(1-吡唑基)-1-丙醇 | 180741-37-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 3-(1-吡唑基)-1-丙醇
• 中文别名: 3-(1-1H-吡唑基)-1-丙醇
• 英文名称: 3-(1H-pyrazol-1-yl)propan-1-ol
• 英文别名: 3-pyrazol-1-ylpropan-1-ol
• CAS: 180741-37-1
• 化学式: C₆H₁₀N₂O
• mdl: MFCD03727229
• 分子量: 126.158
• InChiKey: PMKIEDXXIYUBKC-UHFFFAOYSA-N

物化性质

• 沸点：
  256.4±23.0 °C(Predicted)
• 密度：
  1.11±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  38
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933199090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  3-(1-吡唑基)-1-丙醇 在 钯 二硫化碳 、 N,N-二甲基乙酰胺 、 三氟甲磺酸酐 、 溴 、 三正丁基氢锡 、 sodium hydride 、 sodium carbonate 、 N,N-二异丙基乙胺 、 碘甲烷 作用下， 以 乙腈 为溶剂， 生成 6-{(2R,4S)-4-[(4R,5S,6S)-2-Carboxy-6-((R)-1-hydroxy-ethyl)-4-methyl-7-oxo-1-aza-bicyclo[3.2.0]hept-2-en-3-ylsulfanyl]-pyrrolidin-2-ylmethyl}-2,3-dihydro-1H-pyrazolo[1,2-a]pyrazol-4-ylium; chloride
  参考文献：
  名称：

  Studies on β-lactam antibiotics. Synthesis and antibacterial activity of novel 1β-methylcarbapenems related to FR21818: 5-membered ring analogs

  摘要：

  The synthesis and biological activity of the novel series of 1 beta-methylcarbapenems 1 are described. Most compounds displayed extremely potent antibacterial activity and high renal DHP-1 stability. The best compound in this series, FR21818 (1a) displayed excellent in vivo efficacy against an MRSA infection in mice. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(97)00230-8
• 作为产物：
  描述：

  1H-吡唑-1-丙酸甲酯 在 lithium aluminium tetrahydride 作用下， 以89%的产率得到3-(1-吡唑基)-1-丙醇
  参考文献：
  名称：

  Studies on β-lactam antibiotics. Synthesis and antibacterial activity of novel 1β-methylcarbapenems related to FR21818: 5-membered ring analogs

  摘要：

  The synthesis and biological activity of the novel series of 1 beta-methylcarbapenems 1 are described. Most compounds displayed extremely potent antibacterial activity and high renal DHP-1 stability. The best compound in this series, FR21818 (1a) displayed excellent in vivo efficacy against an MRSA infection in mice. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(97)00230-8

文献信息

• Metal-Free Etherification of Aryl Methyl Ether Derivatives by C–OMe Bond Cleavage
  作者：Xueqiang Wang、Chenchen Li、Xia Wang、Qingli Wang、Xiu-Qin Dong、Abing Duan、Wanxiang Zhao

  DOI：10.1021/acs.orglett.8b01696

  日期：2018.7.20

  A general and efficient protocol was developed for the synthesis of aryl alkyl ethers through metal-free C–OMe bond cleavage under mild reaction conditions. This process displays a wide scope of methoxyarenes and alcohols, including primary, secondary, and tertiary alcohols, as well as natural products, pharmaceuticals, and biologically active alcohols. DFT calculations and experimental results simultaneously

  为在温和的反应条件下通过无金属的C-OMe键裂解合成芳基烷基醚，开发了一种通用而有效的方案。该方法显示出广泛的甲氧基芳烃和醇，包括伯，仲和叔醇，以及天然产物，药物和生物活性醇。DFT计算和实验结果同时证实，钾离子通过与腈的结合在甲氧基的活化中起关键作用，并为S N Ar机制提供了支持。
• [EN] 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS<br/>[FR] PYRAZOLO[1,5-A] PYRAZINES SUBSTITUÉES EN 4,6 EN TANT QU'INHIBITEURS DE LA JANUS KINASE
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2016090285A1

  公开（公告）日：2016-06-09

  Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3 and R4 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of JAK kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.

  公式I的化合物及其立体异构体和药学上可接受的盐和溶剂化合物，在其中R1、R2、R3和R4具有规范中给定的含义，是一种或多种JAK激酶的抑制剂，并且在治疗JAK激酶相关疾病和疾病方面非常有用，如自身免疫疾病、炎症性疾病、移植器官、组织和细胞的排斥反应，以及血液学疾病和恶性肿瘤及其并发症。
• [EN] NOVEL SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND THEIR USE<br/>[FR] NOUVEAUX ACTIVATEURS DE GUANYLATE CYCLASE SOLUBLE ET LEUR UTILISATION
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2015033307A1

  公开（公告）日：2015-03-12

  The invention relates to activators of soluble guanylate cyclase of formula (I) and their use in pharmaceutical compositions, primarily topically administered ophthalmic compositions. The pharmaceutical compositions are useful for reducing intraocular pressure in animals of the mammalian species.

  该发明涉及公式（I）的可溶性鸟苷酸环化酶激活剂及其在制药组合物中的应用，主要是局部给药的眼科组合物。这些制药组合物对于降低哺乳动物种类的动物的眼压是有用的。
• [EN] SMALL MOLECULE MODULATORS OF IL-17<br/>[FR] MODULATEURS À PETITES MOLÉCULES D'IL-17
  申请人：LEO PHARMA AS

  公开号：WO2021255174A1

  公开（公告）日：2021-12-23

  The present invention relates to compounds according to formula I (I) and pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g. dermal diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments.

  本发明涉及公式I（I）的化合物及其药用盐、水合物或溶剂化合物。该发明还涉及所述化合物在治疗中的用途，包括含有所述化合物的药物组合物，用所述化合物治疗疾病的方法，例如皮肤疾病，并且涉及所述化合物用于制造药品。
• [EN] ALKOXY-THIENOPYRIMIDINES AS TGF-BETA RECEPTOR KINASE MODULATORS<br/>[FR] ALCOXYTHIÉNOPYRIMIDINES COMME MODULATEURS DE RÉCEPTEURS KINASES DE TGF-BÊTA
  申请人：MERCK PATENT GMBH

  公开号：WO2010149257A1

  公开（公告）日：2010-12-29

  Novel alkoxy-thienopyrimidine derivatives of formula (I) wherein R1 and R2 have the meaning according to claim 1, are inhibitors of TGF-beta receptor I kinase, and can be employed, inter alia, for the treatment of tumors.

  化合物公式（I）中R1和R2的含义如权利要求1所述，是TGF-beta受体I激酶的抑制剂，可用于治疗肿瘤等疾病。